Literature DB >> 35338090

Ethics and ENDS.

Elizabeth Fenton1, Lindsay Robertson2, Janet Hoek3.   

Abstract

As debate persists over regulating electronic nicotine delivery systems (ENDS), those favouring liberal ENDS policies have advanced rights-based arguments privileging harm reduction to people who smoke over harm prevention to children and never-smokers. Recent ethical arguments advocate regulating ENDS to prioritise their harm reduction potential for people who currently smoke over any future harm to young never-smokers. In this article, we critically assess these arguments, in particular, the assumption that ethical arguments for prioritising the interests of young people do not apply to ENDS. We argue that, when the appropriate comparators are used, it is not clear the weight of ethical argument tips in favour of those who currently smoke and against young never-smokers. We also assert that arguments from a resource prioritisation context are not appropriate for analysing ENDS regulation, because ENDS are not a scarce resource. Further, we reject utilitarian arguments regarding maximising net population health benefits, as these do not adequately consider vulnerable groups' rights, or address the population distribution of benefits and harms. Lastly, we argue that one-directional considerations of harm reduction do not recognise that ENDS potentially increase harm to those who do not smoke and who would not otherwise have initiated nicotine use. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  electronic nicotine delivery devices; harm reduction; public policy

Year:  2022        PMID: 35338090     DOI: 10.1136/tobaccocontrol-2021-057078

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  1 in total

1.  Use of supporting evidence by health and industry organisations in the consultation on e-cigarette regulations in New Zealand.

Authors:  Lucy Hardie; Judith McCool; Becky Freeman
Journal:  PLoS One       Date:  2022-09-29       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.